Evotec SE (EVO) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, good afternoon to all of you in this call. We have a lot to cover today and I'll keep my part very short. So let's move on to cover the housekeeping items on page two. We share the cautionary language here as usual and some statements will be future looking based on information available today and they might be subject to change in future. But now let me hand over to our CEO, Dr. Christian Wojciechowski. Christian, please. Thank you, Volker. Good morning and good afternoon to everyone. It's a pleasure to welcome you all to this call. I'm looking forward to taking you through the progress we've made over the past six months of transition since the announcement of our new strategy. Very pleased with the momentum and high speed of our transformation toward better monetizing our technology leadership. The steps we've taken in the past couple of quarters are a strong fundament for our value creation path and for the execution of our midterm outlook. I'm confident that this will become more visible to you while we lead you through this presentation. Let us now take a closer look at the year-to-date performance. In the first nine months, group revenues landed at 535.1 million euros, which is a 7% decline versus the previous year. This is driven by our DMPD business where we face continued softness in the early drug discovery market, leading to 12% revenue decline. In contrast, our biologics business, JAB, remains on a strong growth path, with plus 11% growth in the first nine months. As mentioned in the last call, we expect the trend in DMPD to continue in the second half of 2025, while for just Avotech Biologics, we anticipate revenue growth to further accelerate. Taking a closer look into the DNPD business, we see several main elements driving past and futur...